Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

被引：0
|
作者：
Hou, Jing-Zhou [1 ,2 ]
Blanc, Simon [3 ]
Maglinte, Gregory A. [4 ]
Vasudevan, Anupama [3 ]
Rui, Anna [3 ]
Gart, Michael [5 ]
Hoa Pham [4 ]
Aton, Lindsay [3 ]
Wang, Brandon [3 ]
Choksi, Rushir [6 ]
机构：
[1] UPMC Hillman Canc Ctr, Lemieux Ctr Blood Canc, Hematol & BMT, Pittsburgh, PA USA
[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[3] Integra Connect PrecisionQ, W Palm Beach, FL USA
[4] BeiGene USA Inc, San Mateo, CA USA
[5] Integra Connect, W Palm Beach, FL USA
[6] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174915
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices
    Hou, Jing-Zhou
    Blanc, Simon
    Maglinte, Gregory A.
    Vasudevan, Anupama
    Rui, Anna
    Gart, Mike
    Pham, Hoa
    Aton, Lindsay
    Wang, Brandon
    Choksi, Rushir J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Treatment Patterns and Clinical Outcomes Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated With Bruton's Tyrosine Kinase Inhibitors (BTKis) in US Community Setting
    Mitul, Gandhi
    Sudeep, Karve
    Bhavini, Srivastava
    Ding, He
    Diala, Harb
    Olga, Ryan
    Juliet, Ndukum
    Ari, Marcus
    Ira, Zackon
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S56 - S56
  • [3] Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL)
    Krackeler, Margaret
    Chee, Bryant
    Orchanian, Arthur K.
    Law, Lisa Y.
    Lopez, Alfredo R.
    Buchanan, Susan
    Maglinte, Gregory A.
    Liu, Raymond
    Zhu, Zheng
    Sakoda, Lori C.
    Tavakoli, Jahan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Real-world treatment patterns of bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US)
    Shah, Bijal D.
    Xue, Mei
    Yang, Keri
    Liu, Sizhu
    Tang, Boxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Real-world risk of bleeding events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with BTKi
    Moslehi, Javid J.
    Wahlstrom, Svea K.
    Teschemaker, Anna
    Mackey, Rachel H.
    DeVincenzo, Diana
    Carabuena, Leslie A.
    Thompson, Samantha L.
    Gordon, Brittaney
    Rosenthal, Ning A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] REAL-WORLD TREATMENT PATTERNS AND CARDIOVASCULAR DISEASE (CVD) BURDEN IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) RECEIVING COVALENT BRUTON'S TYROSINE KINASE INHIBITORS (CBTKIS)
    Dingli, D.
    de Nigris, E.
    Obeng-Kusi, M.
    Leng, S.
    Lodaya, K.
    Weimer, I
    Jiao, W.
    Hyatt, H.
    Yapici, H. O.
    VALUE IN HEALTH, 2024, 27 (06) : S241 - S241
  • [7] PHYSICIAN REPORTED TREATMENT ATTRIBUTES CONSIDERED IN FIRST-LINE AND PERCEPTIONS AROUND BRUTON TYROSINE KINASE INHIBITOR (BTKI) TREATMENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) IN THE US
    Jensen, C.
    Ding, Z.
    Greenwood, T.
    Kluth, C.
    Sanderson, I
    Milloy, N.
    Mavani, H.
    Khan, W.
    Qureshi, Z. P.
    VALUE IN HEALTH, 2023, 26 (12) : S33 - S33
  • [8] Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies
    Tuncer, Hande H.
    Ghosh, Nilanjan
    Fleury, Isabelle
    Leslie, Lori A.
    Manzoor, Beenish S.
    Lamanna, Nicole
    Eyre, Toby A.
    Hill, Brian T.
    Brown, Jennifer R.
    Sinai, Wendy
    Coombs, Catherine C.
    Ujjani, Chaitra
    Roeker, Lindsey E.
    Emechebe, Nnadozie
    Barr, Paul M.
    Davids, Matthew S.
    Martinez-Calle, Nicolas
    Rhodes, Joanna M.
    Lansigan, Frederick
    Pearson, Laurie
    Choi, Yun
    Schuster, Stephen J.
    Skarbnik, Alan P.
    Fakhri, Bita
    Coyle, Michael
    Stephens, Deborah M.
    Thompson, Meghan C.
    Jensen, Christopher E.
    Marx, Steven E.
    Jawaid, Dureshahwar
    Schuh, Anna
    Pivneva, Irina
    Watson, Talissa
    Guerin, Annie
    Shadman, Mazyar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S357 - S358
  • [9] Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients
    Lin, Kevin H.
    Huynh, Lynn
    Yang, Xiaoqin
    Zanardo, Enrico
    Lema, Neema
    Matay, Lisa
    Balasubramanian, Sobana
    Liborski, Daria
    McDonough, Mikaela
    Foreman, Jillian
    Farooqui, Mohammed Z. H.
    De Nigris, Enrico
    Gandra, Shravanthi R.
    Sarpong, Eric M.
    Duh, Mei Sheng
    Brown, Jennifer R.
    Davids, Matthew Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
    Moslehi, Javid J.
    Wahlstrom, Svea K.
    Teschemaker, Anna
    Mackey, Rachel H.
    Devincenzo, Diana
    Carabuena, Leslie A.
    Thompson, Samantha L.
    Gordon, Brittaney-Belle Elizabeth
    Rosenthal, Ning A.
    BLOOD, 2024, 144 : 5109 - 5110
12345